Open Access

Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer

  • Authors:
    • Lizhe Zhu
    • Nan Ma
    • Bin Wang
    • Can Zhou
    • Yu Yan
    • Ke Wang
    • Jianjun He
    • Yu Ren
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/ol.2019.10277
  • Pages: 5469-5480
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The 21‑gene recurrence score (RS) predicts the prognosis of patients with estrogen receptor (ER)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative early‑stage breast cancer and the effectiveness of adding adjuvant chemotherapy on the basis of endocrine therapy to avoid excessive chemotherapy. The present study aimed to analyze clinicopathological characteristics and chemotherapeutic efficacy‑related target genes with the 21‑gene RS in hormone receptor‑positive early‑stage breast cancer in China. The prognostic value of chemotherapeutic efficacy‑related target genes was also examined. In addition, this study investigated the postoperative adjuvant therapeutic decision‑oriented role of 21‑gene RS in hormone receptor‑positive and lymph node‑negative early‑stage breast cancer. In the present retrospective study, 110 ER+/HER2‑ early‑stage breast cancer patients were tested with the 21‑gene RS. The analyses of clinicopathological characteristics and chemotherapeutic efficacy‑related target genes with the 21‑gene RS were performed using the χ2 test, the Wilcoxon rank‑sum test and binary logistic regression. Kaplan‑Meier survival plots were drawn in www.kmplot.com. Furthermore, the McNemar χ2 test was used to compare the changes of treatment decisions before and after the 21‑gene test. The median RS of 110 patients was 16 (range, 2‑47), and patients were categorized as low (59.1%), intermediate (34.5%) or high risk (6.4%). The results revealed that higher body mass index, invasive ductal carcinoma type, higher histological grade, luminal B molecular type and higher thymidylate synthetase (TYMS) and DNA topoisomerase IIα (TOP2A) gene expression levels were more likely to have a higher RS. Kaplan‑Meier plots suggested that expression of TYMS, tubulin β3 class III (TUBB3) and TOP2A genes was significantly associated with relapse‑free survival for ER+ breast cancer. Additionally, prior to 21‑gene RS testing, 61 patients (55%) were recommended adjuvant chemotherapy and endocrine therapy; however, following 21‑gene test, 32 patients (29%) were treated with only adjuvant endocrine therapy. TYMS, TUBB3 and TOP2A gene expression may have prognostic value for ER+ breast cancer. In addition, 21‑gene RS testing may aid to avoid excessive postoperative adjuvant chemotherapy.

References

1 

Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI

2 

Anderson BO and Jakesz R: Breast cancer issues in developing countries: An overview of the Breast Health Global Initiative. World J Surg. 32:2578–2585. 2008. View Article : Google Scholar : PubMed/NCBI

3 

Zeng H, Zheng R, Zhang S, Zou X and Chen W: Female breast cancer statistics of 2010 in China: Estimates based on data from 145 population-based cancer registries. J Thorac Dis. 6:466–470. 2014.PubMed/NCBI

4 

National Bureau of Statistics of China, . China Statistical Yearbook, 2010. China Statistics Press; Beijing: 2010

5 

Salek R, Shahidsales S and Mozafari V: Changing pattern in the clinical presentation of breast cancer in the absence of a screening program over a period of thirty-three years in Iran. Breast. 28:95–99. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Somashekhar SP, Sepúlveda MJ, Puglielli S, Norden AD, Shortliffe EH, Rohit Kumar C, Rauthan A, Arun Kumar N, Patil P, Rhee K, et al: Watson for Oncology and breast cancer treatment recommendations: Agreement with an expert multidisciplinary tumor board. Ann Oncol. 29:418–423. 2018. View Article : Google Scholar : PubMed/NCBI

7 

Gray J and Druker B: Genomics: The breast cancer landscape. Nature. 486:328–329. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H and Toi M: Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat. 112:175–187. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI

11 

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 29:4273–4278. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American Society of Clinical Oncology, : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B and Pusztai L: Multigene prognostic tests in breast cancer: Past, present, future. Breast Cancer Res. 17:112015. View Article : Google Scholar : PubMed/NCBI

14 

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 12:631–635. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB and Kaufman B: Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: A population-based study. Cancer. 112:731–736. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, et al Breast Cancer Intergroup of North America, : Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, et al Panel members, : Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Tsunoda Y, Suzuki K, Tsunoda A, Takimoto M and Kusano M: Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives. Oncol Rep. 23:771–777. 2010.PubMed/NCBI

21 

Yu Z, Sun J, Zhen J, Zhang Q and Yang Q: Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol. 20:871–878. 2005.PubMed/NCBI

22 

Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, et al: In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 28:172–180. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, et al: Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res. 14:4511–4516. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL and Talbot DC: Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res. 9:4682–4688. 2003.PubMed/NCBI

26 

Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Orucevic A, Bell JL, McNabb AP and Heidel RE: Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat. 163:51–61. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S and Lieberman N: The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat. 140:83–92. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, et al: Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: Evidence from a large prospectively designed registry. NPJ Breast Cancer. 3:332017. View Article : Google Scholar : PubMed/NCBI

30 

Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, et al: Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: Evidence from a large prospectively designed registry. NPJ Breast Cancer. 3:322017. View Article : Google Scholar : PubMed/NCBI

31 

Lee MH, Han W, Lee JE, Kim KS, Park H, Kim J, Bae SY, Shin HJ, Lee JW and Lee ES: The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea. Cancer Res Treat. 47:208–214. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M, Khawaja S, Sharaiha Y, et al: A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer. 108:2250–2258. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 28:1671–1676. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Martínez Del Prado P, Alvarez-López I, Domínguez-Fernández S, Plazaola A, Ibarrondo O, Galve-Calvo E, Ancizar-Lizarraga N, Gutierrez-Toribio M, Lahuerta-Martínez A and Mar J: Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: Pooled analysis in 4 Basque Country university hospitals. Clinicoecon Outcomes Res. 10:189–199. 2018. View Article : Google Scholar : PubMed/NCBI

35 

Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, et al: First prospective nulticenter Italian study on the impact of the 21-gene recurrence score in adjuvant clinical decisions for patients with ER positive/HER2 negative breast cancer. Oncologist. 23:297–305. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Yamauchi H, Nakagawa C, Takei H, Chao C, Yoshizawa C, Yagata H, Yoshida A, Hayashi N, Hell S and Nakamura S: Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer. Clin Breast Cancer. 14:191–197. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Eiermann W, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, et al: The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 24:618–624. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhu, L., Ma, N., Wang, B., Zhou, C., Yan, Y., Wang, K. ... Ren, Y. (2019). Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer. Oncology Letters, 17, 5469-5480. https://doi.org/10.3892/ol.2019.10277
MLA
Zhu, L., Ma, N., Wang, B., Zhou, C., Yan, Y., Wang, K., He, J., Ren, Y."Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer". Oncology Letters 17.6 (2019): 5469-5480.
Chicago
Zhu, L., Ma, N., Wang, B., Zhou, C., Yan, Y., Wang, K., He, J., Ren, Y."Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer". Oncology Letters 17, no. 6 (2019): 5469-5480. https://doi.org/10.3892/ol.2019.10277